Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Dec;21(6):631-638.
doi: 10.1111/ajco.14192. Epub 2025 May 26.

The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting

Chanida Vinayanuwattikun  1 , Chalermchai Lertanansit  1   2 , Wasamol Mahaparn  1   3 , Attapol Chotirut  1 , Nicha Zungsontiporn  1 , Suleepon Uttamapinan  1 , Nattaya Sintawichai  1 , Piyada Sitthideatphaiboon  1 , Virote Sriuranpong  1 , Suebpong Tanasanvimon  1
Affiliations
Randomized Controlled Trial

The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting

Chanida Vinayanuwattikun et al. Asia Pac J Clin Oncol. 2025 Dec.

Abstract

Background: Addition of olanzapine to NK-1 receptor antagonist regimen improves chemotherapy-induced nausea and vomiting (CINV) prevention for highly emetogenic chemotherapies (HECs). However, the benefit of addition of NK-1 receptor antagonist to olanzapine regimen has not been demonstrated. This study compared the efficacy of upfront and subsequent addition of netupitant- to olanzapine-containing regimen for preventing CINV from high-dose cisplatin (≥ 75 mg/m2).

Patient and methods: The double-blind placebo-controlled trial randomized patients receiving high-dose cisplatin to upfront and subsequent netupitant arms. In upfront netupitant arm, patients received NEPA (a combination of netupitant and palonosetron), dexamethasone, and olanzapine since first cycle. In subsequent netupitant arm, patients received olanzapine, dexamethasone, and ondansetron in first cycle but received NEPA, dexamethasone, and olanzapine in second cycle if no complete response (CR). After preplanned analysis, the initial dexamethasone dose in netupitant regimen was modified from 4 to 8 mg on Days 2-4. The primary endpoint was the overall CR rate of two cycles.

Results: Between January 2019 and December 2020, 51 and 49 patients were randomly assigned to upfront and subsequent netupitant arms, respectively. CR rates in acute (0-24 h), delayed (> 24-120 h), and overall periods were 93.0% versus 77.4% (p = 0.003), 75.5% versus 68.8% (p = 0.31), and 73.3% and 67.7% (p = 0.34) in upfront and subsequent netupitant arms, respectively. After amendment to increase dexamethasone in netupitant regimen, first-cycle CR rates in acute, delayed, and overall periods were 95.2% versus 87.7% (p = 0.34), 85.7% versus 73.5% (p = 0.26), and 85.7% and 69.4% (p = 0.26) in 4-drug and 3-drug groups, respectively. Among 15 patients crossing over to receive netupitant regimen in second cycle, CR was 46.6%.

Conclusion: In this Phase II trial, there was no significant improvement in overall CR when patients received upfront netupitant compared to subsequent addition of netupitant to an olanzapine regimen in patients receiving high-dose cisplatin chemotherapy.

Keywords: chemotherapy‐induced nausea and vomiting; highly emetogenic chemotherapy; netupitant‐containing regimen.

PubMed Disclaimer

References

    1. M. J. Bergexr, R. Agarwal, S. Anand, et al., NCCN guidelines version 1.2023 antiemesis continue, http://www.nccn. (2023).
    1. J. Herrstedt, R. Clark‐Snow, C. H. Ruhlmann, et al., “2023 MASCC and ESMO Guideline Update for the Prevention of Chemotherapy‐ and Radiotherapy‐Induced Nausea and Vomiting,” ESMO Open 9, no. 2 (2024): 102195.
    1. P. J. Hesketh, M. G. Kris, E. Basch, et al., “Antiemetics: ASCO Guideline Update,” Journal of Clinical Oncology 38, no. 24 (2020): 2782–2797.
    1. M. Aapro, A. Carides, B. L. Rapoport, et al., “Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety,” Oncologist 20 (2015): 450–458.
    1. P. J. Hesketh, G. Rossi, G. Rizzi, et al., “Efficacy and Safety of NEPA, an Oral Combination of Netupitant and Palonosetron, for Prevention of Chemotherapy‐Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy: A Randomized Dose‐Ranging Pivotal Study,” Annals of Oncology 25 (2014): 1340–1346.

Publication types

MeSH terms

LinkOut - more resources